These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882 [TBL] [Abstract][Full Text] [Related]
5. [RODOS: risperidone olanzapine drug outcome studies in schizophrenia]. De Beauchamp I; Giraud-Baro E; Gury C Encephale; 2002; 28 Spec No 2 Pt 2():S33-4. PubMed ID: 12587356 [No Abstract] [Full Text] [Related]
6. Service use and costs of treating schizophrenia with atypical antipsychotics. Lewis M; McCrone P; Frangou S J Clin Psychiatry; 2001 Oct; 62(10):749-56. PubMed ID: 11816863 [TBL] [Abstract][Full Text] [Related]
7. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Kelly DL; Nelson MW; Love RC; Yu Y; Conley RR Psychiatr Serv; 2001 May; 52(5):676-8. PubMed ID: 11331805 [TBL] [Abstract][Full Text] [Related]
8. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Zhao Z Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967 [TBL] [Abstract][Full Text] [Related]
9. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. Taylor DM; Wright T; Libretto SE; J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664 [TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Revicki DA Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231 [TBL] [Abstract][Full Text] [Related]
11. Olanzapine: an updated review of its use in the management of schizophrenia. Bhana N; Foster RH; Olney R; Plosker GL Drugs; 2001; 61(1):111-61. PubMed ID: 11217867 [TBL] [Abstract][Full Text] [Related]
12. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients. Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491 [TBL] [Abstract][Full Text] [Related]
13. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Almond S; O'Donnell O Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493 [TBL] [Abstract][Full Text] [Related]
14. Use of atypical antipsychotics in a Veterans Affairs hospital. Schwartz TL; Saba M; Hardoby W; Virk S; Masand PS Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1207-10. PubMed ID: 12452548 [TBL] [Abstract][Full Text] [Related]
15. Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates. Kasper S; Küfferle B J Clin Psychopharmacol; 1998 Aug; 18(4):353-6. PubMed ID: 9690709 [No Abstract] [Full Text] [Related]
16. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Procyshyn RM; Zerjav S Clin Ther; 1998; 20(6):1203-17; discussion 1192-3. PubMed ID: 9916613 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Jerrell JM Schizophr Bull; 2002; 28(4):589-605. PubMed ID: 12795493 [TBL] [Abstract][Full Text] [Related]
18. New antipsychotic drugs produce better outcomes. Healthc Benchmarks; 1997 Oct; 4(10):142-4. PubMed ID: 10173374 [No Abstract] [Full Text] [Related]
19. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Kasper S; Hale A; Azorin JM; Möller HJ Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070 [No Abstract] [Full Text] [Related]
20. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Kasper S; Jones M; Duchesne I; Int Clin Psychopharmacol; 2001 Jul; 16(4):189-96. PubMed ID: 11459332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]